Literature DB >> 16145572

Masters of angiogenesis.

Robert M Strieter.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16145572     DOI： 10.1038/nm0905-925

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  20 in total

Review 1.  The role of CXC chemokines in pulmonary fibrosis.

Authors:  Robert M Strieter; Brigitte N Gomperts; Michael P Keane
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 2.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 3.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

Review 4.  Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  S Barratt; A Millar
Journal:  QJM       Date:  2014-01-22

5.  Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo.

Authors:  Sung Keun Jung; Ki Won Lee; Sanguine Byun; Eun Jung Lee; Jong-Eun Kim; Ann M Bode; Zigang Dong; Hyong Joo Lee
Journal:  Carcinogenesis       Date:  2009-12-11       Impact factor: 4.944

6.  Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications.

Authors:  Georg Lurje; Marc Schiesser; Andreas Claudius; Paul Magnus Schneider
Journal:  J Oncol       Date:  2009-11-05       Impact factor: 4.375

Review 7.  CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.

Authors:  Timothy R Donahue; O Joe Hines
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

8.  Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.

Authors:  G Lurje; H Husain; D G Power; D Yang; S Groshen; A Pohl; W Zhang; Y Ning; P C Manegold; A El-Khoueiry; S Iqbal; L H Tang; M A Shah; H-J Lenz
Journal:  Ann Oncol       Date:  2009-07-21       Impact factor: 32.976

9.  Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.

Authors:  Anne M Schultheis; Georg Lurje; Katrin E Rhodes; Wu Zhang; Dongyun Yang; Agustin A Garcia; Robert Morgan; David Gandara; Sidney Scudder; Amit Oza; Hal Hirte; Gini Fleming; Lynda Roman; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

10.  OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model.

Authors:  Patricia Coutinho de Souza; Nataliya Smith; Richard Pody; Ting He; Charity Njoku; Robert Silasi-Mansat; Florea Lupu; Bill Meek; Hong Chen; Yunzhou Dong; Debra Saunders; Albert Orock; Erik Hodges; Sarah Colijn; Nadezda Mamedova; Rheal A Towner
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.